WBC Growth Factors: ASCO Guideline Update.

Methods

A systematic reviewidentified randomized controlled trials (RCTs), meta-analyses, and systematic reviews that addressed use of CSFs for the prevention or treatment of neutropenic events, or for mobilization of stem cells, in adults with cancer.

系统综述确定了随机对照试验（RCTs）、荟萃分析和系统综述，这些研究涉及在成年癌症患者中使用CSFs预防或治疗中性粒细胞减少症事件，或用于干细胞动员。

PubMed and the Cochrane Library were searched for articles published from September 1, 2014, to August 22, 2025.

检索了PubMed和Cochrane图书馆，以查找2014年9月1日至2025年8月22日发表的文章。

ASCO convened an Expert Panel to review the evidence and formulate recommendations.

ASCO召集了一个专家小组，以审查证据并制定建议。

Results

The updated systematic reviewincluded 33 RCTs and 16 systematic reviews.

更新的系统综述包括了33项随机对照试验(RCTs)和16项系统综述。

Additions to the body of evidence include approval of new CSFs and additional biosimilars, and approval of an additional CXCR4 inhibitor that may be used with CSFs for the mobilization of hematopoietic stem cells.

证据体系的增加包括了新的集落刺激因子(CSFs)的批准、额外的生物类似药的批准，以及可能与CSFs联合使用的另一种CXCR4抑制剂的批准，该抑制剂用于造血干细胞的动员。

recommendations

Prophylactic use of CSFs to reduce the risk of febrile neutropenia is warranted when the risk of febrile neutropenia from chemotherapy is approximately 20% or higher and no other equally effective and safe regimen that does not require CSFs is available.

当化疗导致发热性中性粒细胞减少症的风险约为20%或更高，并且没有其他同样有效且安全且不需要使用粒细胞集落刺激因子（CSFs）的方案时，预防性使用CSFs以降低发热性中性粒细胞减少症的风险是合理的。

For patients receiving chemotherapy with a <20% risk of febrile neutropenia, primary prophylaxis with a CSF may be warranted if patients are at a high risk of febrile neutropenia based on age, medical history, or disease characteristics.

对于接受化疗且发热性中性粒细胞减少症风险低于20%的患者，如果基于年龄、病史或疾病特征判断患者发热性中性粒细胞减少症的风险较高，那么使用粒细胞集落刺激因子（CSFs）进行初级预防可能是合理的。

For stem-cell mobilization, CSFs may be used either alone, after chemotherapy, or in combination with plerixafor or motixafortide.

在干细胞动员方面，CSFs可以单独使用，或在化疗后使用，或与plerixafor或motixafortide联合使用。

The guideline also provides information about the dosing and selection of CSFs.Additional information is available at www.asco.org/supportive-care-guidelines.

该指南还提供了关于CSFs剂量和选择的信息。更多详细信息可在www.asco.org/supportive-care-guidelines中找到。